Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.
about
Poly-arginine peptides reduce infarct volume in a permanent middle cerebral artery rat stroke model(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein TauCollapsin response mediator protein 2 (CRMP2) interacts with N-methyl-D-aspartate (NMDA) receptor and Na+/Ca2+ exchanger and regulates their functional activity.Modulation of nociceptive ion channels and receptors via protein-protein interactions: implications for pain relief.Current and Future Issues in the Development of Spinal Agents for the Management of Pain.Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides.A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors.Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.The Neuroprotective Peptide Poly-Arginine-12 (R12) Reduces Cell Surface Levels of NMDA NR2B Receptor Subunit in Cortical Neurons; Investigation into the Involvement of Endocytic Mechanisms.Characterisation of neuroprotective efficacy of modified poly-arginine-9 (R9) peptides using a neuronal glutamic acid excitotoxicity model.Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat.Disrupting USP5/Cav3.2 interactions protects female mice from mechanical hypersensitivity during peripheral inflammationPerinatal Hypoxic-Ischemic Encephalopathy and Neuroprotective Peptide Therapies: A Case for Cationic Arginine-Rich Peptides (CARPs)CRMP2 and voltage-gated ion channels: potential roles in neuropathic pain
P2860
Q36007755-6CA3CE34-86D6-4C48-B4B8-7AAF96135169Q37074848-7B46ABEC-ABB8-4CDC-9E6C-16E6014497B5Q37089388-95D2C5E5-92CB-4872-96C1-5D93D9EA7DEEQ37635778-C2585384-018D-490F-883D-1DAB9B19A35CQ38514549-29CF15CC-97D3-4D09-8B8E-617A7E116905Q38727831-6D9AE11A-FFA8-4B7F-ADB1-FDDC04532816Q40349390-8F167EB9-A3A5-482A-BFFF-FEBA43A2AADEQ41202785-9F60FA73-EA40-4F94-935C-B73F0F352B5AQ43075742-AED0C5C2-1987-4583-97C5-CEEB5EEA7214Q48212687-0A574A28-3282-4ABA-9F57-35E6BFFD1204Q48430070-7B075F2D-638D-49D5-845E-BD4616251969Q50094040-C8827EC3-790D-4E89-8573-BAB0BC21E31BQ57810843-546F9E89-FD0E-4667-B503-D691068E6BE8Q57929840-894DD2A8-99C2-47E1-8AF4-06FA62921F04Q58582878-C796B35E-A18A-4C75-A799-291CDC600052
P2860
Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Challenging the catechism of t ...... eractions with CRMP2 peptides.
@en
Challenging the catechism of t ...... eractions with CRMP2 peptides.
@nl
type
label
Challenging the catechism of t ...... eractions with CRMP2 peptides.
@en
Challenging the catechism of t ...... eractions with CRMP2 peptides.
@nl
prefLabel
Challenging the catechism of t ...... eractions with CRMP2 peptides.
@en
Challenging the catechism of t ...... eractions with CRMP2 peptides.
@nl
P2860
P921
P1433
P1476
Challenging the catechism of t ...... eractions with CRMP2 peptides.
@en
P2093
Polina Feldman
P2860
P356
10.1016/J.NEULET.2013.06.057
P407
P478
P577
2013-07-03T00:00:00Z